Lyka Labs Ltd
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
- Market Cap ₹ 394 Cr.
- Current Price ₹ 111
- High / Low ₹ 177 / 90.2
- Stock P/E 54.1
- Book Value ₹ 37.8
- Dividend Yield 0.00 %
- ROCE 8.29 %
- ROE 7.03 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 2.93 times its book value
- Company has a low return on equity of -0.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Jun 2014 15m | Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
87 | 90 | 57 | 78 | 42 | 41 | 41 | 62 | 164 | 81 | 106 | 135 | 134 | |
88 | 72 | 49 | 56 | 42 | 40 | 44 | 48 | 67 | 65 | 92 | 117 | 117 | |
Operating Profit | -2 | 18 | 8 | 22 | -1 | 1 | -3 | 14 | 98 | 16 | 15 | 18 | 17 |
OPM % | -2% | 20% | 14% | 28% | -1% | 2% | -8% | 23% | 59% | 19% | 14% | 13% | 13% |
24 | 5 | 11 | -0 | 3 | 2 | -25 | 1 | -2 | -4 | 2 | 2 | 2 | |
Interest | 24 | 18 | 11 | 17 | 8 | 6 | 19 | 26 | 20 | 12 | 5 | 2 | 3 |
Depreciation | 5 | 4 | 3 | 6 | 6 | 4 | 8 | 8 | 15 | 14 | 12 | 6 | 7 |
Profit before tax | -7 | 1 | 5 | -1 | -11 | -7 | -55 | -18 | 60 | -13 | -1 | 11 | 10 |
Tax % | 0% | 0% | 0% | -66% | -3% | -124% | 0% | -21% | 34% | 1% | 143% | 28% | |
-7 | 1 | 5 | -0 | -11 | 2 | -55 | -14 | 40 | -13 | -2 | 8 | 7 | |
EPS in Rs | -3.37 | 0.63 | 2.19 | -0.09 | -3.85 | 0.61 | -19.31 | -5.04 | 13.91 | -4.33 | -0.69 | 2.31 | 2.05 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 27% |
3 Years: | -6% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 18% |
3 Years: | -42% |
TTM: | 488% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 45% |
3 Years: | -7% |
1 Year: | -7% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | 10% |
3 Years: | 0% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 |
Reserves | 40 | 38 | 43 | 52 | 69 | 70 | -10 | -24 | 16 | 46 | 66 | 99 |
140 | 109 | 106 | 112 | 102 | 91 | 137 | 163 | 129 | 74 | 59 | 39 | |
61 | 64 | 57 | 57 | 46 | 59 | 66 | 46 | 35 | 28 | 28 | 31 | |
Total Liabilities | 263 | 233 | 228 | 243 | 245 | 249 | 221 | 213 | 209 | 179 | 186 | 206 |
94 | 62 | 60 | 86 | 81 | 76 | 102 | 95 | 90 | 66 | 56 | 84 | |
CWIP | 22 | 27 | 30 | 24 | 26 | 30 | 26 | 24 | 18 | 16 | 23 | 1 |
Investments | 63 | 63 | 63 | 62 | 62 | 62 | 32 | 32 | 32 | 32 | 32 | 32 |
84 | 82 | 75 | 70 | 75 | 80 | 61 | 61 | 68 | 65 | 75 | 88 | |
Total Assets | 263 | 233 | 228 | 243 | 245 | 249 | 221 | 213 | 209 | 179 | 186 | 206 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
55 | 29 | 8 | 20 | 7 | 18 | -11 | 6 | 77 | 7 | 3 | 3 | |
-25 | 30 | 5 | -5 | -3 | -3 | 0 | 0 | -4 | 7 | -9 | -13 | |
-29 | -63 | -13 | -15 | -4 | -16 | 20 | -8 | -63 | -20 | 3 | 5 | |
Net Cash Flow | 2 | -3 | 0 | -0 | -1 | -0 | 8 | -2 | 9 | -7 | -3 | -5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 107 | 116 | 169 | 113 | 265 | 263 | 59 | 58 | 39 | 78 | 88 | 110 |
Inventory Days | 58 | 90 | 74 | 93 | 124 | 98 | 99 | 67 | 97 | 87 | 81 | 86 |
Days Payable | 235 | 283 | 323 | 283 | 536 | 519 | 430 | 301 | 109 | 103 | 93 | 95 |
Cash Conversion Cycle | -70 | -77 | -80 | -76 | -147 | -159 | -272 | -176 | 26 | 62 | 77 | 100 |
Working Capital Days | -343 | -313 | -491 | -398 | -768 | -172 | -296 | -154 | -137 | 16 | 28 | 54 |
ROCE % | -1% | 9% | 9% | 10% | -3% | -0% | -5% | 5% | 50% | 3% | 3% | 8% |
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
3h - Summary of Lyka Labs' 46th AGM held on 1 Aug 2025 with resolutions and voting details.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
5h - Q1 FY26 unaudited results approved; Company Secretary resigned; new Internal Auditor appointed.
-
Announcement under Regulation 30 (LODR)-Change in Management
5h - Q1 2025 unaudited results approved; company secretary resigned; new internal auditor appointed for FY26.
-
Results
7h - Q1 2025 unaudited results approved; Company Secretary resigned; new internal auditor appointed for FY 2025-26.
-
Board Meeting Outcome for Outcome
7h - Q1 FY26 unaudited results; Company Secretary resigned; new internal auditor appointed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.